GORE MEDICAL RECEIVES BREAKTHROUGH DEVICE DESIGNATION FOR THE GORE® EXCLUDER® THORACOABDOMINAL BRANCH ENDOPROSTHESIS
CAUTION: Investigational device. Limited by United States law to investigational use.
Apr 12, 2022
First Patient Enrolled in Gore TAG Thoracic Branch Endoprosthesis LSA Feasibility Study
Multi-Center Study to Assess Feasibility of Gore Device to Treat Historically Challenging Patient Population
Gore Marks Two-Year Primary Endpoint Follow-up Milestone in Study of GORE® CARDIOFORM Septal Occluder for Patent Foramen Ovale (PFO) Closure
Completion of follow -up paves way for REDUCE Clinical Study data submission to FDA for PFO indication
First Patients Enrolled in the Gore RELINE MAX Clinical Study
108 patient trial to add evidence for treatment of in-stent restenosis using the GORE® VIABAHN® Endoprosthesis
Gore Applauds Medicare Announcement to Reclassify Endovascular Abdominal Aneurysm Repairs
Decision comes after two-year effort to improve the alignment of payment with cost of treatment for abdominal aortic aneurysms
Physicians Report Early Successes Across Multiple Applications in First-in-Human Uses of GORE® SYNECOR Preperitoneal Biomaterial Hernia Repair Device
New three-layer hybrid biomaterial, ideal for TAR procedures, offering permanent strength and rapid tissue generation for single-stage repairs
W. L. Gore & Associates Receives Innovative Technology Designation from Vizient, Inc. for GORE® SYNECOR Biomaterial
Designation recognizes products that bring improvements to the healthcare industry
GORE® DrySeal Flex Introducer Sheath Advances Care through Access
New sheath provides exceptional access to challenging anatomies and branch vessels